ASVRX
Price
$9.78
Change
+$0.05 (+0.51%)
Updated
Jun 2 closing price
Net Assets
3.06B
RSQCX
Price
$15.10
Change
+$0.06 (+0.40%)
Updated
Jun 2 closing price
Net Assets
472.52M
Interact to see
Advertisement

ASVRX vs RSQCX

Header iconASVRX vs RSQCX Comparison
Open Charts ASVRX vs RSQCXBanner chart's image
ASVRX vs RSQCX Comparison Chart in %
View a ticker or compare two or three
VS
ASVRX vs. RSQCX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASVRX is a Buy and RSQCX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
ASVRX has more cash in the bank: 3.06B vs. RSQCX (473M). RSQCX pays higher dividends than ASVRX: RSQCX (1.32) vs ASVRX (0.54). ASVRX was incepted earlier than RSQCX: ASVRX (16 years) vs RSQCX (23 years). RSQCX (2.45) is less costly to investors than ASVRX (1.58). ASVRX is a more actively managed with annual turnover of: 39.00 vs. RSQCX (12.00). RSQCX has a lower initial minimum investment than ASVRX: RSQCX (2000) vs ASVRX (2500). RSQCX annual gain was more profitable for investors over the last year : 22.94 vs. ASVRX (8.16). ASVRX return over 5 years is better than : -11.82 vs. RSQCX (-18.09).
ASVRXRSQCXASVRX / RSQCX
Total Expense Ratio1.582.2471%
Annual Report Gross Expense Ratio1.582.4564%
Fund Existence16 years23 years-
Gain YTD13.40318.99171%
Front LoadN/AN/A-
Min. Initial Investment25002000125%
Min. Initial Investment IRAN/AN/A-
Net Assets3.06B473M647%
Annual Yield % from dividends0.541.3241%
Returns for 1 year8.1622.9436%
Returns for 3 years11.354.43257%
Returns for 5 years-11.82-18.0965%
Returns for 10 years26.97-11.75-230%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRNS90.562.47
+2.80%
Transcat
ZGN14.600.11
+0.76%
Ermenegildo Zegna NV
DOUG1.77-0.02
-1.12%
Douglas Elliman
MDLN33.19-2.56
-7.16%
Medline Inc
ERNA8.07-1.04
-11.46%
Ernexa Therapeutics Inc.